Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0828 CFIUS
BioCentury & Getty Images

Regulation

Biotech may have side-stepped CFIUS’ worst case scenario  

The inability to define emerging and foundational technology means most foreign investments in U.S. biotechs will avoid scrutiny

The Commerce Department’s inability to define emerging and foundational technologies means most foreign investments in U.S. biotechs will avoid government scrutiny.

Aug 28, 2020 | 7:58 PM GMT

So far, biotech has avoided the nightmare scenario in which almost any private company seeking foreign investment would come under government scrutiny. Recently proposed legislation could inject additional uncertainty, however, by changing who gets to decide which technologies are critical to national security.

The expansion of the jurisdiction of the Committee on Foreign Investment in the United States (CFIUS) in 2018 raised alarm across industries as it gave CFIUS power to investigate many

Read the full 1283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE